DRAFT landscape of COVID-19 candidate vaccines – 2 July 2020 18 candidate vaccines in clinical evaluation Platform Type of candidate vaccine Developer Coronavirus target NonReplicating Viral Vector ChAdOx1-S University of Oxford/AstraZeneca SARS-CoV2 NonReplicating Viral Vector Adenovirus Type 5 Vector CanSino Biological Inc./Beijing Institute of Biotechnology SARS-CoV2 RNA LNPencapsulated mRNA Moderna/NIAID DNA DNA plasmid vaccine with electroporation Inactivated Inactivated Inactivated Inactivated Inactivated Protein Subunit Current stage of clinical evaluation/regulatory statusCoronavirus candidate Same platform for non-Coronavirus candidates Phase 3 ISRCTN89951424 Phase2b/3 2020-001228-32 Phase 1/2 PACTR202006922165132 2020-001072-15 Phase 2 ChiCTR2000031781 Phase 1 ChiCTR2000030906 MERS, influenza, TB, Chikungunya, Zika, MenB, plague SARS-CoV2 Phase 2 NCT04405076 Phase 1 NCT04283461 multiple candidates Inovio Pharmaceuticals/ International Vaccine Institute SARS-CoV2 Phase 1/2 NCT04447781 NCT04336410 multiple candidates Wuhan Institute of Biological Products/Sinopharm Beijing Institute of Biological Products/Sinopharm SARS-CoV2 Phase 1/2 ChiCTR2000031809 SARS-CoV2 Phase 1/2 ChiCTR2000032459 Inactivated + alum Sinovac SARS-CoV2 Phase 1/2 NCT04383574 NCT04352608 SARS Novavax SARS-CoV2 Phase 1/2 NCT04368988 RSV; CCHF, HPV, VZV, EBOV RNA Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M 3 LNP-mRNAs BioNTech/Fosun Pharma/Pfizer SARS-CoV2 Phase 1/2 2020-001038-36 NCT04368728 Inactivated Inactivated Institute of Medical Biology SARS-CoV2 , Chinese Academy of Medical Sciences Phase 1 NCT04412538 DNA DNA Vaccine (GX-19) Adeno-based Genexine Consortium SARS-CoV2 Gamaleya Research Institute SARS-CoV2 Native like Trimeric subunit Spike Protein vaccine Clover Biopharmaceuticals Inc./GSK/Dynavax SARS-CoV2 Phase 1 NCT04445389 Phase 1 NCT04436471 NCT04437875 Phase 1 NCT04405908 NonReplicating Viral Vector Protein Subunit Ebola HIV, REV Influenza DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents. Protein Subunit Adjuvanted recombinant protein (RBDDimer) Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences Vaxine Pty Ltd/Medytox SARS-CoV2 Phase 1 NCT04445194 Protein Subunit RNA Recombinant spike protein with Advax™ adjuvant LNP-nCoVsaRNA SARS-CoV2 Phase 1 NCT04453852 Imperial College London SARS-CoV2 mRNA Curevac SARS-CoV2 Phase 1 ISRCTN17072692 Phase 1 NCT04449276 RNA RNA mRNA People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech. SARS-CoV2 MERS EBOV; LASV, MARV, Inf (H7N9), RABV RABV, LASV, YFV; MERS, InfA, ZIKV, DENV, NIPV Phase 1 ChiCTR2000034112 129 candidate vaccines in preclinical evaluation Platform Type of candidate vaccine Developer DNA DNA plasmid vaccine S,S1,S2,RBD &N National Research Centre, Egypt DNA DNA with electroporation DNA DNA with electroporation Karolinska Institute / Cobra Biologics (OPENCORONA Project) Chula Vaccine Research Center DNA DNA plasmid vaccine DNA DNA DNA DNA DNA DNA DNA Inactivated Inactivated Inactivated Inactivated SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical Osaka University/ AnGes/ Takara Bio DNA Takis/Applied DNA Sciences/Evvivax Plasmid DNA, Needle- Immunomic Therapeutics, Free Delivery Inc./EpiVax, Inc./PharmaJet DNA plasmid vaccine Zydus Cadila SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical DNA vaccine DNA vaccine DNA vaccine bacTRL-Spike Inactivated whole virus Inactivated BioNet Asia University of Waterloo Entos Pharmaceuticals Symvivo National Research Centre, Egypt SARS-CoV2 SARS-CoV2 SARS-CoV2 SARS-CoV2 SARS-CoV2 Pre-Clinical Pre-Clinical Pre-Clinical Pre-Clinical Pre-Clinical Beijing Minhai Biotechnology Co., Ltd. Osaka University/ BIKEN/ NIBIOHN Sinovac/Dynavax SARS-CoV2 Pre-Clinical SARS-CoV2 SARS-CoV2 Pre-Clinical Pre-Clinical Valneva/Dynavax SARS-CoV2 Pre-Clinical Research Institute for Biological SARS-CoV2 Safety Problems, Rep of Kazakhstan Codagenix/Serum Institute of India SARS-CoV2 Pre-Clinical Indian Immunologicals Ltd/Griffith University SARS-CoV2 Pre-Clinical Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis SARS-CoV2 Pre-Clinical Inactivated TBD Inactivated + CpG 1018 Inactivated + CpG 1018 Inactivated Live Attenuated Virus Live Attenuated Virus NonReplicating Viral Vector Codon deoptimized live attenuated vaccines Codon deoptimized live attenuated vaccines Adeno-associated virus vector (AAVCOVID) Inactivated Coronavirus Current stage of clinical target evaluation/regulatory status- Coronavirus candidate SARS-CoV2 Pre-Clinical Pre-Clinical Same platform for nonCoronavirus candidates SARS HAV, InfA, ZIKV, FMD, SIV, RSV, DENV DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents. NonReplicating Viral Vector NonReplicating Viral Vector NonReplicating Viral Vector MVA encoded VLP GeoVax/BravoVax SARS-CoV2 Pre-Clinical LASV, EBOV, MARV, HIV Ad26 Janssen Pharmaceutical Companies SARS-CoV2 Pre-Clinical Ebola, HIV, RSV Replication defective Simian Adenovirus (GRAd) encoding SARS-CoV-2 S MVA-S encoded ReiThera/LEUKOCARE/Univercells SARS-CoV2 Pre-Clinical DZIF – German Center for Infection Research/IDT Biologika GmbH SARS-CoV2 Pre-clinical MVA-S IDIBAPS-Hospital Clinic, Spain SARS-CoV2 Pre-clinical adenovirus-based NasoVAX expressing SARS2-CoV spike protein Non[E1-, E2b-, E3-] hAd5Replicating COVID19Viral Vector Spike/Nucleocapsid NonAd5 S (GREVAX™ Replicating platform) Viral Vector NonOral Ad5 S Replicating Viral Vector Nonadenovirus-based + Replicating HLA-matched Viral Vector peptides NonOral Vaccine platform Replicating Viral Vector Altimmune SARS-CoV2 Pre-Clinical influenza ImmunityBio, Inc. & NantKwest, Inc. SARS-CoV2 Pre-Clinical Greffex SARS-CoV2 Pre-Clinical flu, Chik, Zika, EBOV, LASV, HIV/SIV,Cancer MERS Stabilitech Biopharma Ltd SARS-CoV2 Pre-Clinical Valo Therapeutics Ltd Pan-Corona Pre-Clinical Vaxart SARS-CoV2 Pre-Clinical NonReplicating Viral Vector NonReplicating Viral Vector NonReplicating Viral Vector MVA expressing structural proteins Centro Nacional Biotecnología (CNB-CSIC), Spain SARS-CoV2 Pre-Clinical Dendritic cell-based vaccine University of Manitoba SARS-CoV2 Pre-Clinical University of Georgia/University of Iowa SARS-CoV2 Pre-Clinical MERS Bharat Biotech/Thomas Jefferson University SARS-CoV2 Pre-Clinical HeV, NiV, EBOV, LASSA, CCHFV, MERS National Research Centre, Egypt SARS-CoV2 Pre-Clinical National Center for Genetic SARS-CoV2 Engineering and Biotechnology (BIOTEC) /GPO, Thailand Helix Biogen Consult, Ogbomoso & SARS-CoV2 Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria. National Research Centre, Egypt SARS-CoV2 Pre-Clinical University of San Martin and CONICET, Argentina Chulalongkorn University/GPO, Thailand AdaptVac (PREVENT-nCoV consortium) SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical Nonreplicating viral vector Nonreplicating viral vector NonReplicating Viral Vector parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein NonRecombinant Replicating deactivated rabies Viral Vector virus containing S1 NonInfluenza A H1N1 Replicating vector Viral Vector NonInactivated Flu-based Replicating SARS-CoV2 vaccine + Viral Vector Adjuvant Protein Subunit Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit S,N,M&S1 protein Protein Subunit RBD protein fused with Fc of IgG + Adj. Capsid-like Particle Many Zika, VZV, HSV-2 and Norovirus InfA, CHIKV, LASV, NORV; EBOV, RVF, HBV, VEE Multiple candidates Pre-Clinical Pre-Clinical DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents. Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Drosophila S2 insect ExpreS2ion cell expression system VLPs Peptide antigens IMV Inc formulated in LNP S protein WRAIR/USAMRIID SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical National Institute of Infectious SARS-CoV2 Disease, Japan VLP-recombinant Osaka University/ BIKEN/ National SARS-CoV2 protein + Adjuvant Institutes of Biomedical Innovation, Japan microneedle arrays S1 Univ. of Pittsburgh SARS-CoV2 subunit Peptide Vaxil Bio SARS-CoV2 Pre-Clinical Adjuvanted protein subunit (RBD) Peptide Biological E Ltd SARS-CoV2 Pre-Clinical Flow Pharma Inc SARS-CoV2 Pre-Clinical S protein AJ Vaccines SARS-CoV2 Pre-Clinical Ii-Key peptide Generex/EpiVax SARS-CoV2 Pre-Clinical S protein EpiVax/Univ. of Georgia SARS-CoV2 Pre-Clinical Protein Subunit EPVCoV-19 S protein (baculovirus production) gp-96 backbone EpiVax SARS-CoV2 Pre-Clinical Sanofi Pasteur/GSK SARS-CoV2 Pre-Clinical Heat Biologics/Univ. Of Miami SARS-CoV2 Pre-Clinical Molecular clamp stabilized Spike protein Peptide vaccine University of Queensland/GSK/Dynavax SARS-CoV2 Pre-Clinical FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo Baylor College of Medicine SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical iBio/CC-Pharming SARS-CoV2 Pre-Clinical Saint-Petersburg scientific research SARS-CoV2 institute of vaccines and serums Pre-Clinical Innovax/Xiamen Univ./GSK SARS-CoV2 Pre-Clinical VIDO-InterVac, University of Saskatchewan OncoGen SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical MIGAL Galilee Research Institute SARS-CoV2 Pre-Clinical LakePharma, Inc. SARS-CoV2 Pre-Clinical S protein +Adjuvant Subunit vaccine S1 or RBD protein Subunit protein, plant produced Recombinant protein, nanoparticles (based on S-protein and other epitopes) COVID-19 XWG-03 truncated S (spike) proteins Adjuvanted microsphere peptide Synthetic Long Peptide Vaccine candidate for S and M proteins Oral E. coli-based protein expression system of S and N proteins Nanoparticle vaccine Influenza Pre-Clinical Pre-Clinical MERS Pre-Clinical Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, BreastCA vaccine Influenza, HIV, SARS-CoV H7N9 Influenza, SARSCoV NSCLC, HIV, malaria, Zika Nipah, influenza, Ebola, Lassa Ebola SARS HPV DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents. Protein Subunit Protein Subunit Protein Subunit Protein subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Plant-based subunit (RBD-Fc + Adjuvant) OMV-based vaccine Baiya Phytopharm/ Chula Vaccine Research Center Quadram Institute Biosciences SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical OMV-based vaccine BiOMViS Srl/Univ. of Trento SARS-CoV2 Pre-Clinical structurally modified spherical particles of the tobacco mosaic virus (TMV) Spike-based Lomonosov Moscow State University SARS-CoV2 Pre-Clinical rubella, rotavirus University of Alberta SARS-CoV2 Pre-Clinical Hepatitis C Recombinant S1-Fc fusion protein Recombinant protein AnyGo Technology SARS-CoV2 Pre-Clinical Yisheng Biopharma SARS-CoV2 Pre-Clinical Recombinant S protein in IC-BEVS Orally delivered, heat stable subunit S-2P protein + CpG 1018 Peptides derived from Spike protein Protein Subunit Vabiotech SARS-CoV2 Pre-Clinical Applied Biotechnology Institute, Inc. Medigen Vaccine Biologics Corporation/NIAID/Dynavax Axon Neuroscience SE SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical RBD-based MOGAM Institute for Biomedical Research, GC Pharma Neovii/Tel Aviv University SARS-CoV2 Pre-Clinical RBD-based Kentucky Bioprocessing, Inc SARS-CoV2 Pre-Clinical Outer Membrane Vesicle (OMV)subunit Outer Membrane Vesicle(OMV)-peptide Spike-based (epitope screening) YF17D Vector Intravacc/Epivax SARS-CoV2 Pre-Clinical Intravacc/Epivax SARS-CoV2 Pre-Clinical ImmunoPrecise/LiteVax BV SARS-CoV2 Pre-Clinical KU Leuven SARS-CoV2 Pre-Clinical Zydus Cadila SARS-CoV2 Pre-Clinical Institute Pasteur/Themis/Univ. of Pittsburg Center for Vaccine Research/Merck FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo DZIF – German Center for Infection Research/CanVirex AG Tonix Pharma/Southern Research SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-clinical SARS-CoV2 Pre-Clinical BiOCAD and IEM SARS-CoV2 Pre-Clinical Zika, H7N9, CHIKV Smallpox, monkeypox Influenza FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo SARS-CoV2 Pre-Clinical Influenza Fundação Oswaldo Cruz and Instituto Buntantan SARS-CoV2 Pre-Clinical Influenza University of Hong Kong SARS-CoV2 Pre-Clinical Protein Subunit Protein Subunit Replicating Viral Vector Replicating Measles Vector Viral Vector Replicating Measles Vector Viral Vector Replicating Viral Vector Replicating Viral Vector Replicating Viral Vector Replicating Viral Vector Measles Vector Measles Virus (S, N targets) Horsepox vector expressing S protein Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal) Replicating Recombinant vaccine Viral Vector based on Influenza A virus, for the prevention of COVID19 (intranasal) Replicating Attenuated Influenza Viral Vector expressing an antigenic portion of the Spike protein Replicating Influenza vector Viral Vector expressing RBD Flu A, plague West nile, chik, Ebola, Lassa, Zika DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents. Replicating ReplicationViral Vector competent VSV chimeric virus technology (VSVΔG) delivering the SARSCoV-2 Spike (S) glycoprotein. Replicating VSV-S Viral Vector Replicating VSV vector Viral Vector Replicating VSV-S Viral Vector Replicating M2-deficient single Viral Vector replication (M2SR) influenza vector Replicating Newcastle disease Viral Vector virus vector (NDVSARS-CoV-2/Spike) Replicating Avian paramyxovirus Viral Vector vector (APMV) RNA LNP-mRNA RNA LNP-mRNA RNA RNA RNA LNP-encapsulated mRNA cocktail encoding VLP LNP-encapsulated mRNA encoding RBD IAVI/Merck SARS-CoV2 Pre-Clinical Ebola, Marburg, Lassa University of Western Ontario SARS-CoV2 Pre-Clinical HIV, MERS FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo Israel Institute for Biological Research/Weizmann Institute of Science UW–Madison/FluGen/Bharat Biotech SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ. The Lancaster University, UK SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical Translate Bio/Sanofi Pasteur CanSino Biologics/Precision NanoSystems Fudan University/ Shanghai JiaoTong University/RNACure Biopharma Fudan University/ Shanghai JiaoTong University/RNACure Biopharma Centro Nacional Biotecnología (CNB-CSIC), Spain SARS-CoV2 SARS-CoV2 Pre-Clinical Pre-Clinical SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical University of Tokyo/ Daiichi-Sankyo SARS-CoV2 Pre-Clinical BIOCAD SARS-CoV2 Pre-Clinical RNAimmune, Inc. SARS-CoV2 Pre-Clinical FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo China CDC/Tongji University/Stermina Arcturus/Duke-NUS SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical Chula Vaccine Research Center/University of Pennsylvania SARS-CoV2 Pre-Clinical RNA Replicating Defective SARS-CoV-2 derived RNAs LNP-encapsulated mRNA Liposomeencapsulated mRNA Several mRNA candidates mRNA RNA mRNA RNA mRNA RNA LNP-mRNA RNA SARS-CoV2 Pre-Clinical RNA mRNA in an intranasal eTheRNA delivery system mRNA Greenlight Biosciences SARS-CoV2 Pre-Clinical RNA mRNA IDIBAPS-Hospital Clinic, Spain SARS-CoV2 Pre-Clinical VLP Enveloped Virus-Like Particle (eVLP) S protein integrated in HIV VLPs VBI Vaccines Inc. SARS-CoV2 Pre-Clinical IrsiCaixa AIDS Research/IRTACReSA/Barcelona Supercomputing Centre/Grifols Mahidol University/ The Government Pharmaceutical Organization (GPO)/Siriraj Hospital Navarrabiomed, Oncoimmunology group SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical SARS-CoV2 Pre-Clinical Saiba GmbH SARS-CoV2 Pre-Clinical RNA RNA RNA VLP VLP VLP + Adjuvant VLP Virus-like particles, lentivirus and baculovirus vehicles Virus-like particle, based on RBD VLP influenza MERS multiple candidates DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents. VLP VLP displayed on virus-like particles Plant-derived VLP Medicago Inc./ Université Laval SARS-CoV2 Pre-Clinical Imophoron Ltd and Bristol University’s Max Planck Centre Doherty Institute SARS-CoV2 Pre-Clinical VLP ADDomerTM multiepitope display Unknown SARS-CoV2 Pre-Clinical VLP VLP OSIVAX Pre-Clinical VLP eVLP ARTES Biotechnology SARS-CoV1 SARS-CoV2 SARS-CoV2 VLP VLPs peptides/whole virus Unknown Univ. of Sao Paulo SARS-CoV2 Pre-Clinical Tulane University SARS-CoV2 Pre-Clinical Unknown Pre-Clinical Flu, Rotavirus, Norovirus, West Nile virus, Cancer malaria DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.